Drug resistance in Leishmania: does it really matter?

Research output: Contribution to journalReviewpeer-review

Abstract

Treatment failure (TF) jeopardizes the management of parasitic diseases, including leishmaniasis. From the parasite's point of view, drug resistance (DR) is generally considered as central to TF. However, the link between TF and DR, as measured by in vitro drug susceptibility assays, is unclear, some studies revealing an association between treatment outcome and drug susceptibility, others not. Here we address three fundamental questions aiming to shed light on these ambiguities. First, are the right assays being used to measure DR? Second, are the parasites studied, which are generally those that adapt to in vitro culture, actually appropriate? Finally, are other parasite factors - such as the development of quiescent forms that are recalcitrant to drugs - responsible for TF without DR?

Original languageEnglish
JournalTrends In Parasitology
Volume39
Issue number4
Pages (from-to)251-259
Number of pages9
ISSN1471-4922
DOIs
Publication statusPublished - Apr-2023

Keywords

  • Humans
  • Leishmania
  • Antiprotozoal Agents/pharmacology
  • Leishmaniasis/drug therapy
  • Drug Resistance

Fingerprint

Dive into the research topics of 'Drug resistance in Leishmania: does it really matter?'. Together they form a unique fingerprint.

Cite this